“To combat rising healthcare expenditure the European countries are focusing on developing EPO biosmilars” says RNCOS

Biosimilars are biopharmaceutical drugs that are designed to have properties, which are similar to the ones of biologic drugs. The biosimilars have no clinically meaningful differences from the reference product.

According to a new report published by RNCOS, named, “European Erythropoietin Market Outlook 2022”, since the year of their introduction, the EPO biosimilars have gained a lot of popularity. The biologics are more complex and costly to develop, whereas the biosimilars being the generic version of these biologics are a cost-effective alternative to these high priced drugs. The biosimilars cost about 25% less than the innovator drug, due to the reduced clinical trials. This results in higher adoption rate of these biosimilar drugs as compared to innovators. This reason is also compelling high number of pharmaceutical companies in Europe to create a strong pipeline of innovative EPO biosimilars.

Currently, several EPO biosimilars are in various stages of clinical development. Some of them are HX575 and HX 575 s.c., amongst others. The pharmaceutical companies in Europe that are developing a strong pipeline of erythropoietin biosimilars include Novartis and Roche amongst others.

Researchers are also engaged in developing the fourth generation of erythropoietin. The fourth generation EPOs is being developed by making use of adenovirus, which contains a piece of erythropoietin-DNA, from humans, genetically incorporated into it. Once these erythropoietin biosimilars enter the European market, they are going to strongly drive the growth of the European erythropoietin market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM863.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm